EA202190360A1 - Комбинированная терапия - Google Patents

Комбинированная терапия

Info

Publication number
EA202190360A1
EA202190360A1 EA202190360A EA202190360A EA202190360A1 EA 202190360 A1 EA202190360 A1 EA 202190360A1 EA 202190360 A EA202190360 A EA 202190360A EA 202190360 A EA202190360 A EA 202190360A EA 202190360 A1 EA202190360 A1 EA 202190360A1
Authority
EA
Eurasian Patent Office
Prior art keywords
combination therapy
inhibitor
effective amount
kinase
methods
Prior art date
Application number
EA202190360A
Other languages
English (en)
Russian (ru)
Inventor
Дэниел П. Голд
Original Assignee
Мей Фарма, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мей Фарма, Инк filed Critical Мей Фарма, Инк
Publication of EA202190360A1 publication Critical patent/EA202190360A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202190360A 2018-08-14 2019-08-13 Комбинированная терапия EA202190360A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862718925P 2018-08-14 2018-08-14
PCT/US2019/046405 WO2020036995A1 (en) 2018-08-14 2019-08-13 Combination therapy

Publications (1)

Publication Number Publication Date
EA202190360A1 true EA202190360A1 (ru) 2021-07-15

Family

ID=69525833

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190360A EA202190360A1 (ru) 2018-08-14 2019-08-13 Комбинированная терапия

Country Status (9)

Country Link
US (1) US20210161909A1 (enExample)
JP (1) JP2021534114A (enExample)
CN (1) CN112839651A (enExample)
AU (1) AU2019322858A1 (enExample)
EA (1) EA202190360A1 (enExample)
IL (1) IL280729A (enExample)
MX (1) MX2021001764A (enExample)
TW (1) TW202021592A (enExample)
WO (1) WO2020036995A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
IL315315A (en) * 2022-03-01 2024-10-01 Mei Pharma Inc Combined treatment with PI3K inhibitor and PD1 inhibitor
CN118949002A (zh) * 2024-10-15 2024-11-15 杭州阿克索生物科技有限责任公司 一种宫颈癌细胞抑制组合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101209397B1 (ko) * 2006-06-21 2012-12-06 피라말 라이프 사이언시스 리미티드 증식성 질환 치료용 광학이성적으로 순수한, 증식성 질환 치료용 플라본 유도체 및 이의 제조방법
CN107501241B (zh) * 2011-03-28 2020-10-13 梅制药公司 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途
WO2014055647A1 (en) * 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2016024232A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
IL295472B2 (en) * 2016-03-28 2024-10-01 Presage Biosciences Inc Pharmaceutical combinations for the treatment of cancer
CN109982687A (zh) * 2016-09-19 2019-07-05 梅制药公司 联合疗法
EP3630118A4 (en) * 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
MX2020001727A (es) * 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.

Also Published As

Publication number Publication date
WO2020036995A1 (en) 2020-02-20
MX2021001764A (es) 2021-04-19
JP2021534114A (ja) 2021-12-09
US20210161909A1 (en) 2021-06-03
CN112839651A (zh) 2021-05-25
AU2019322858A1 (en) 2021-04-01
TW202021592A (zh) 2020-06-16
IL280729A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
EA202092154A1 (ru) Комбинированная терапия
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
MX391720B (es) Terapia combinada para tratar cáncer.
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
JO3589B1 (ar) مثبطات كيناز البروتين c وطرق استخداماتها
JOP20190151B1 (ar) مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2017000628A (es) Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia.
MX390121B (es) Combinaciones de un inhibidor de btk y un inhibidor de pi3k para tratar neoplasias malignas hematológicas.
MX373231B (es) Agente anticancerigeno.
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
CL2020000270A1 (es) Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf.
MX2020001727A (es) Terapia de combinacion.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2019013862A (es) Terapia de combinacion.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
EA202192964A1 (ru) Комбинированная терапия
MX2021001764A (es) Terapia de combinacion.
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
PH12021551276A1 (en) Combination therapy for the treatment of cancer